An open-label randomized controlled trial trial to investigate efficacy of ertapenem compared with group 2 carbapenems in extended-spectrum beta-lactamase-producing Gram-negative bacterial infections

Trial Profile

An open-label randomized controlled trial trial to investigate efficacy of ertapenem compared with group 2 carbapenems in extended-spectrum beta-lactamase-producing Gram-negative bacterial infections

Completed
Phase of Trial: Phase II

Latest Information Update: 16 May 2016

At a glance

  • Drugs Ertapenem (Primary) ; Carbapenems
  • Indications Gram-negative infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 May 2016 New trial record
    • 12 Apr 2016 Results presented at the 26th European Congress of Clinical Microbiology and Infectious Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top